The stem cell therapy project Blue4Therapy brought to a highly successful close

The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential for AcouSort. Behind the project were the University of Southern Denmark, BlueCell Therapeutics, Novozymes and AcouSort. AcouSort's contribution to the project has been to develop a module for the purification of stem cells in a point-of-care environment (POC). The project has now been successfully finalized and the applications and hardware that AcouSort has developed within the Blue4Therapy framework have significantly strengthened the company’s position within the cell therapy industry.

The Blue4Therapy project has allowed AcouSort to develop an application with the ability to, from a starting material containing up to 25 different types of cells, accurately and with great precision select, purify, and up-concentrate the cells needed to treat erectile dysfunction. Through AcouSort’s unique acoustic separation technology, the new application has robust up-concentration capabilities, and produces the required concentration levels of the target cells to optimize treatment success rate. The application can easily be adapted to meet the needs of other stem cell therapies – something which will be very valuable for AcouSort’s continued efforts targeting the stem cell industry.

Within the framework of the Blue4Therapy project, AcouSort has also designed and built a demonstrator device. The device is intended to be used by BlueCell to further characterize and isolate stem cells from adipose tissue. The device also provides the opportunity to evaluate integration of the AcouWash technology in third party instruments, making it a valuable tool for other potential partners and customers of AcouSort.

“The Blue4Therapy has provided AcouSort with new knowledge, a unique application for selection, purification, and concentration of cells to be used in advanced cell therapies as well as a demonstrator device that could prove very useful for AcouSort going forward. All in all, the Blue4Therapy project has significantly strengthened our cell therapy position,” says AcouSort’s CEO Torsten Freltoft.

View the video to learn more about the Blue4Therapy project: https://www.youtube.com/watch?v=Ac5B9ekmqsA